FT.com / Search

1-10 of 14 results for MYLAN PHARMACEUTICALS, INC.

Sort by:

Relevance
Date

January 12, 2005
Mylan backs away from King merger
Mylan Laboratories retreated from its $3.7bn deal to buy King Pharmaceuticals, citing King's recent financial...ending the controversial merger. Mylan, the US drugmaker specialising in...notably its hypertension drug Altace - Mylan pursued it for its sales force to help diversify its business into branded pharmaceuticals and launch its own hypertension drug... By Christopher Bowe and James Politi in New York
September 13, 2009
‘Vote-buying’ controversy rumbles on
In 2004, Mylan Laboratories, a US pharmaceutical company, agreed to buy rival King Pharmaceuticals for a substantial premium to its market...not perceived to be quite so good for Mylan; its shares fell on the announcement...promptly bought a 9.9 per cent stake in Mylan, becoming its largest shareholder... By Steve Johnson
January 13, 2005
Mylan retreats over King deal
Mylan Laboratories yesterday retreated from...controversial $3.7bn offer to buy King Pharmaceuticals, citing the target's recent financial restatements as the reason. Mylan, the US drugmaker specialising in...over several years was necessary. Mylan said any restatement would violate its agreement. King Pharmaceuticals did not return calls. By Christopher Bowe and James Politi in New York
January 13, 2005
Mylan goes cold on bid for King
Mylan Laboratories yesterday retreated from its $3.7bn offer to buy King Pharmaceuticals, citing King's recent financial...ending the controversial merger. Mylan, the US drugmaker specialising in...notably its hypertension drug Altace - Mylan pursued it for its sales force to help diversify its business into branded pharmaceuticals and launch its own hypertension drug... By Christopher Bowe and James Politi in New York
March 1, 2005
Mylan-King merger off
Mylan Laboratories, a US generic pharmaceuticals company, has dropped its $4bn all-stock offer for King Pharmaceuticals, a drugs distributor, seven months...took a near 10 per cent stake in Mylan and led an investor campaign against...regulators. The end of plans to merge Mylan and King comes amid a battle for control of key assets in the generic pharmaceuticals industry. Last week, Novartis... By James Politi in New York
November 29, 2009
Warning sounded over drug tenders
Large-scale government tenders for generic medicines are threatening the future of the off-patent pharmaceuticals industry, the new president of the trade body has warned. Didier Barret, who runs the Europe, Middle East and Africa operations for Mylan, one of the world’s largest generic drugs companies, called for a “sustainable pricing system without which... By Andrew Jack in London
May 13, 2007
Merck sells generics unit to Mylan for €4.9bn
...agreed to sell its generics division to Mylan Laboratories of the US for €4.9bn...global scale. The deal highlights Mylan’s aggressive quest to keep pace with...s largest generics groups, Teva Pharmaceuticals of Israel and Sandoz, a unit of...ingredient maker. Robert Coury, Mylan chief executive, said the acquisition...ongoing worldwide consolidation in the pharmaceuticals sector, whether research-based... By Andrew Jack in London and Christopher Bowe in New York
May 14, 2007
Mylan in €4.9bn generics deal
...agreed to sell its generics division to Mylan Laboratories of the US for €4.9bn...global scale. The deal highlights Mylan's aggressive quest to keep pace...s largest generics groups, Teva Pharmaceuticals of Israel and Sandoz, a unit of Swiss...ingredient maker. Robert Coury, Mylan chief executive, said the acquisition...ongoing worldwide consolidation in the pharmaceuticals sector, whether research-based groups... By Andrew Jack in London and Chris Bowe inNew York
June 15, 2005
Mylan seeks partner to market new drug
...Analysts have been in favour of Mylan striking a deal to help sell nebivolol. The drug is the cornerstone of Mylan's push into more profitable branded pharmaceuticals, to diversify away from its lower...develop nebivolol for heart failure. Mylan's failed acquisition of King Pharmaceuticals was aimed at acquiring a salesforce... By Christopher Bowe in New York
February 28, 2005
Wall St in reverse despite fresh merger wave
...57.75. Also, One planned marriage was called off: King Pharmaceuticals and the general drug maker Mylan Laboratories scuttled their merger over a disagreement on terms. Mylan shares rose 48 cents, or 3.9 per cent to $17.60, while... By Stephen Schurr and Andrei Postelnicu in New York